Managing Elevated LDL-C: New Guidelines and New Agents

Elevated low-density lipoprotein cholesterol (LDL-C) levels are a major contributor to arteriosclerotic cardiovascular disease (ASCVD). In 2018, the AHA and ACC jointly published an updated guideline on blood cholesterol management, providing new guidance on primary and secondary ASCVD prevention including LDL-C threshold levels for treatment and outlining the role of more recently approved agents. In addition, the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) published guidelines in 2019 that recommended lower LDL-C goal levels, a new definition of high-risk patients that expanded the number of patients in this group, and recommends more aggressive use of non-statin agents compared to the 2018 ACC/AHA guidelines.

Unfortunately, mean LDL-C levels in the US continue to rise. To achieve the AHA’s 2030 impact goal, the new guidelines and new agents will need to be incorporated into clinical practice. This educational activity, “Managing Elevated LDL-C: New Guidelines and New Agents” will provide cardiologists with information about the new guidelines, expert opinion on the role of agents recently approved by the FDA after the guideline publication, and a review of results from trials of agents in late stage development.

Jointly provided by Boston University School of Medicine and Rockpointe

Patient education resources provided in collaboration with the Foundation of the National Lipid Association

This program is supported by educational funding provided by Amgen and Novartis Pharmaceuticals Corporation.